Resolution of obesity comorbidities was achieved in the majority of patients: 9 out of 11 of the hypertensive patients (antihypertensive medication was withdrawn in all of them except for two patients who remained on angiotensin-converting enzyme inhibitors), 5 out of the 6 type 2 diabetic patients (insulin was withdrawn in 3 of them, two others stopped antidiabetic oral agents and one was still on metformin) and 5 out of the 9 patients with hyperlipidemia (4 remained on statins). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.